Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06631053 · Lance Bollinger

FIT Exercise in 30d of ULLS-induced Muscle Disuse

What this study is about

This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and balance regulation.

View original scientific description

This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and balance regulation.

Interventions

OTHER

velocity-based FIT (VBFIT)

Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study. All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week

OTHER

No Exercise

Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study. All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study.

Primary outcome measures

Voluntary activation

Time frame: Baseline, day 13, and day 30

Voluntary activation of the quadriceps will be assessed with electrical stimulation of the femoral nerve before, during, and after a maximal voluntary isometric contraction (MVIC) using the interpolated twitch technique.

Twitch Properties-Electromechanical Delay

Time frame: Baseline, day 13, and day 30

Electromechanical delay will be calculated as the time difference between the onset of electrical impulse and onset of torque development during femoral nerve stimulation. This will be measured before and after a maximal voluntary isometric contraction.

Twitch Properties-Rate of Torque Development

Time frame: Baseline, day 13, and day 30

Rate of Torque Development will be calculated as the change in torque divided by the change in time in the linear phase between 20 and 80% of peak twitch torque during femoral nerve stimulation. This will be measured before and after a maximal voluntary isometric contraction.

Twitch Properties-Time to peak Tension

Time frame: Baseline, day 13, and day 30

Time to peak tension will be calculated as the time difference between the onset of electrical impulse and peak twitch torque during femoral nerve stimulation. This will be measured before and after a maximal voluntary isometric contraction.

Twitch Properties-Peak Twitch Torque

Time frame: Baseline, day 13, and day 30

Peak twitch torque during femoral nerve stimulation will be calculated as the highest torque output immediately (approximately 200ms) following femoral nerve stimulation. This will be measured before and after a maximal voluntary isometric contraction.

Twitch Properties-Relaxation Rate

Time frame: Baseline, day 13, and day 30

Relaxation rate will be calculated as the change in torque divided by the change in time during the relaxation phase of twitch following femoral nerve stimulation. This will be measured before and after a maximal voluntary isometric contraction.

Post activation Potentiation

Time frame: Baseline, day 13, and day 30

Post-activation will be calculated as the percentage difference in peak twitch torque in femoral nerve stimulation before and after a maximal voluntary isometric contraction.

Motor unit action potential train (MUAPT) firing rate

Time frame: Baseline, day 13, and day 30

Firing rate of individual motor units of the vastus lateralis (VL) will be assessed with high density surface electromyography (EMG) using four-pin high density surface electromyography electrodes. Firing rate at 30, 60, and 90% MVIC will be reported. Motor unit firing rate will also be reported during static stance. Participants will use a screen displaying real-time torque output. Participants will voluntarily increase torque (5 seconds), hold at a pre-determined torque level (10 seconds), and gradually reduce force back to resting (5 seconds) with the knee held in a fixed position. This test will be completed with a 10s isometric hold at 30, 60, and 90% of maximal voluntary isometric force.

Motor unit action potential train (MUAPT) recruitment threshold.

Time frame: Baseline, day 13, and day 30

Recruitment threshold of individual motor units of the VL will be assessed with high density surface electromyography using four-pin high density surface electromyography electrodes. Recruitment threshold will be measured during isometric ramp contractions of the quadriceps Participants will use a screen displaying real-time torque output. Participants will voluntarily increase torque (5 seconds), hold at a pre-determined torque level (10 seconds), and gradually reduce force back to resting (5 seconds) with the knee held in a fixed position. This test will be completed with a 10s isometric hold at 30, 60, and 90% of maximal voluntary isometric force.

Motor unit action potential train (MUAPT) de-recruitment threshold.

Time frame: Baseline, day 13, and day 30

De-recruitment threshold of individual motor units f the VL will be assessed with high density surface electromyography using four-pin high density surface electromyography electrodes. Recruitment threshold will be measured during isometric ramp contractions of the quadriceps Participants will use a screen displaying real-time torque output. Participants will voluntarily increase torque (5 seconds), hold at a pre-determined torque level (10 seconds), and gradually reduce force back to resting (5 seconds) with the knee held in a fixed position. This test will be completed with a 10s isometric hold at 30, 60, and 90% of maximal voluntary isometric force.

Muscle size

Time frame: Baseline and day 30

Muscle size will be measured by MRI. Anatomical MRI scans will allow for assessment of anatomical cross sectional area.

Muscle Physiological cross-sectional area

Time frame: Baseline and day 30

Diffusion tensor imaging (DTI) will be used to assess muscle volume and fascicle length. Physiological cross-sectional area will be calculated as Muscle volume divided by fascicle length.

Muscle Fractional Anisotropy

Time frame: Baseline and day 30

Diffusion tensor imaging (DTI) will be used to assess anisotropic measures. A ratio of the diffusivity in the principal planes will be used to calculate fractional anisotropy.

Muscle Diffusion properties

Time frame: Baseline and day 30

Diffusion tensor imaging (DTI) will be used to assess rate of water diffusion in three principal planes. We will report rates of water diffusion in three ways: 1) mean diffusivity (average rate in all three plane), 2) axial diffusivity (rate of diffusion along primary axis), and 3) radial diffusivity (rate of diffusion perpendicular to the primary axis).

Muscle cross-sectional area (Ultrasound)

Time frame: Baseline, day 13, and day 30

cross-sectional area of the vastus lateralis and rectus femoris will be measured by ultrasonography

Fascicle length

Time frame: Baseline, day 13, and day 30

Panoramic views of the mid-portion of the VL will be measured by ultrasonography

Pennation angle

Time frame: Baseline, day 13, and day 30

Pennation angle of the mid-portion of the vastus lateralis will be assessed by ultrasonography

Voluntary Isokinetic Muscle Strength

Time frame: Baseline, day 13, and day 30

Maximal voluntary isokinetic concentric strength of the knee extensors/flexors and ankle dorsi-/plantar-flexors will be assessed at 60 deg/s

Voluntary Isometric Muscle Strength

Time frame: Baseline, day 13, and day 30

Maximal voluntary isometric strength of the knee extensors/flexors and ankle dorsi-/plantar-flexors will be assessed during a (10 seconds) maximal effort contraction.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Regularly engaging in aerobic exercise (\> 150min/wk) and resistance exercise (\>1 time per week) for the past 12 months
  • Education greater than or equal to bachelor's degree (any field)

Exclusion criteria

  • Waist circumference \< 55cm or \> 90cm (F) and \< 75cm or \> 100cm (M)
  • Body mass index \< 18.5 or \> 29.9
  • Shoe size \< 25 or \>29cm.
  • Not regularly engaging in exercise for previous 12 months
  • Tobacco use within previous 6 months
  • Blood clotting disorder
  • Heart arrhythmia
  • Implanted device which could negatively be affected by electrical impulse or strong magnetic field such as pacemaker, internal defibrillator, or cochlear implant
  • Diagnosed cardiovascular, pulmonary, renal, or metabolic disease
  • Pregnancy (within previous 6 months)
  • Oral contraceptive use (within previous three months)
  • High resting blood pressure (\>140 systolic and/or \> 90 diastolic)
  • Currently or previously undergone gender-affirming therapy (hormone therapy or sexual reassignment surgery)
  • Low back or leg injury in previous 6 months
  • Currently taking medication to assist with sleep
  • Muscle, bone, or joint injury that limits physical activity within previous 6 months
  • Neurological disorder which affects balance (such as multiple sclerosis or Parkinson's disease)

Where

  • Lexington, Kentucky

Collaborators

University of Louisville, National Aeronautics and Space Administration (NASA)

Related conditions & keywords

Muscle AtrophyMuscle Weaknessspaceflightunweightingdisuseexercise

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Oct 24, 2025 · Source of record for eligibility and locations

📊
1 of 16 participants interested
6% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Lexington

Kentucky

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Pulmonary Hypertension Trials by City

Browse all pulmonary hypertension clinical trials in these cities — not just this study.

Looking for Muscle Atrophy Treatment in Lexington?

Join others in Kentucky exploring innovative treatment options through clinical research

Muscle Atrophy Treatment Options in Lexington, Kentucky

If you're searching for Muscle Atrophy treatment in Lexington, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Lexington and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Muscle Atrophy. All study-related care is provided at no cost to participants.

Local Sites
1 locations in Kentucky
Now Enrolling
Up to 16 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Muscle Atrophy?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Muscle Atrophy

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Muscle Atrophy Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06631053. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.